



# TAKE THE GUESSWORK OUT OF **HEART FAILURE** MANAGEMENT

The CardioMEMS™ HF System provides the actionable data you need to empower intelligent remote monitoring.



## THE GROWING PROBLEM OF HEART FAILURE

Heart failure is a serious disease with major implications in the U.S.

### EVERY HEART FAILURE HOSPITALIZATION INCREASES YOUR PATIENT'S RISK FOR DEATH<sup>1</sup>



**6.2 MILLION**  
people have heart failure<sup>2</sup>




**1 IN 9 DEATHS**  
each year from heart failure<sup>3</sup>



**\$30.7 BILLION**  
annual cost of heart failure<sup>4</sup>

### EARLY INSIGHT WITH THE CARDIOMEMS™ HF SYSTEM


Take action as filling pressures rise—weeks before decompensation.




Graph adapted from Adamson PB. Pathophysiology of the transition from chronic compensated and acute decompensated heart failure: new insights from continuous monitoring devices. *Current Heart Failure Reports*. 2009;6:287-292.

## HOW THE CARDIOMEMS™ HF SYSTEM WORKS

Empowers care teams to proactively manage heart failure.



The PA sensor is inserted via right heart catheterization.



Patient takes daily sensor reading from the comfort of their home.




Data wirelessly transmitted to Merlin.net™ Patient Care Network, a secure website that easily presents PA pressure data to inform proactive treatment modifications.



Clinician reviews data and contacts patient, as necessary.

# LEADING THE WAY IN HEART FAILURE MANAGEMENT

As the heart failure remote monitoring system with the most clinical evidence, the CardioMEMS™ HF System has proven to be much more than just a predictor of impending hospitalizations.



## REDUCTION IN HOSPITALIZATIONS

Reduction in hospitalizations for both types of heart failure and the ONLY management tool proven for HFpEF patients:

↓ **60%**

reduction in HFpEF hospitalizations<sup>5</sup>

↓ **57%**

reduction in heart failure hospitalizations<sup>5</sup>

↓ **54%**

reduction in HFrEF hospitalizations<sup>5</sup>



## REDUCTIONS IN 30-DAY READMISSIONS

Reducing the need for readmissions:

↓ **78%**

heart failure specific<sup>6</sup>

↓ **58%**

All cause<sup>6</sup>



## REDUCTION IN MORTALITY

Reducing the overall mortality rate:

↓ **30%**

lower mortality rate<sup>7</sup>



The CardioMEMS HF System changed all of our lives. Her doctor gets the chance to see how she is doing from afar to be able to treat her. They can maintain or alter her medications, or prescribe things she wouldn't normally be able to take had she not been monitored remotely. I'm not sure there's much more of an upgrade of technology than the CardioMEMS HF System.


– Jennifer M., Beth's daughter

## STAYING HOME—AND OUT OF THE HOSPITAL

The CardioMEMS™ HF System is the personalized approach your patients deserve. It helps them stay out of the hospital and reconnect with their lives, by restoring the ability to engage in simple day-to-day activities.



Remote monitoring makes it possible to manage patients while decreasing frequency of clinic appointments.



You can send customizable messages about lifestyle or medication changes to patients via the myCardioMEMs app.

### DO YOU HAVE PATIENTS WHO CAN BENEFIT?

**The CardioMEMS HF System is indicated for patients with:**

- NYHA Class III heart failure,<sup>8</sup> and
- One heart failure hospitalization in the last 12 months<sup>8</sup>

**Patients who most commonly receive the CardioMEMS HF System:**

- Are on GDMT and have fluid volumes that are hard to know or measure
- Have HFpEF or HFrEF
- Would benefit from remote monitoring because they live far from a clinic

# MAKING HEART FAILURE MORE THAN MANAGEABLE.

Learn more about the CardioMEMS™ HF System  
by visiting [Cardiovascular.Abbott/CardioMEMS](https://www.Cardiovascular.Abbott/CardioMEMS).

## References

1. Setoguchi S, et al. Repeated hospitalizations predict mortality in the community population with heart failure. *Am Heart J*. 2007;154(2):260-266.
2. Virano SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics—2020 update: a report from the American Heart Association. *Circulation*. 2020;141:e139-e596.
3. Mozaffarian paper: Mozaffarian D, Benjamin EJ, Go AS, et al. on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. *Circulation*. 2016;133:e38-e360.
4. Centers for Disease Control and Prevention (CDC) Heart Failure Fact Sheet. [https://www.cdc.gov/dhdsp/data\\_statistics/fact\\_sheets/fs\\_heart\\_failure.htm](https://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_heart_failure.htm) (accessed August 6, 2018).
5. Shavelle D., et al. Lower rates of heart failure and all-cause hospitalizations during pulmonary artery pressure-guided therapy for ambulatory heart failure. *Circulation: Heart Failure*. Advance online publication. <https://doi.org/10.1161/CIRCHEARTFAILURE.119.006863>
6. Adamson, et al. Pulmonary artery pressure-guided heart failure management reduces 30-day readmissions. *Circulation: Heart Failure*. 2016;115:002600.
7. Abraham J, et al. Association of ambulatory hemodynamic monitoring with clinical outcomes in a concurrent matched cohort analysis. *JAMA Cardiology*. 2019;4(6):556-563.
8. Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomized controlled trial. *The Lancet*. 2011;377(9766):658-666.

## Abbott

One St. Jude Medical Dr., St. Paul, MN 55117 USA, Tel: 1 651 756 2000  
[Cardiovascular.Abbott.com](https://www.Cardiovascular.Abbott.com)

## RX ONLY

**Brief Summary:** Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

**CardioMEMS™ HF System Indications and Usage:** The CardioMEMS™ HF System is indicated for wirelessly measuring and monitoring pulmonary artery (PA) pressure and heart rate in New York Heart Association (NYHA) Class III heart failure patients who have been hospitalized for heart failure in the previous year. The hemodynamic data are used by physicians for heart failure management and with the goal of reducing heart failure hospitalizations.

**CardioMEMS™ HF System Contraindications:** The CardioMEMS HF System is contraindicated for patients with an inability to take dual antiplatelet or anticoagulants for one month post implant.

**CardioMEMS™ HF System Potential Adverse Events:** Potential adverse events associated with the implantation procedure include, but are not limited to, the following: Infection, Arrhythmias, Bleeding, Hematoma, Thrombus, Myocardial infarction, Transient ischemic attack, Stroke, Death, and Device embolization.

**myCardioMEMS™ Mobile App Limitations:** Patients must use their own Apple® or Android® mobile device to receive and transmit information to the myCardioMEMS™ mobile app. To do so the device must be powered on, app must be installed and data coverage (cellular or Wi-Fi) available. The myCardioMEMS™ app can provide notification of medication adjustments and reminders, requests for lab work and acknowledgment that the PA pressure readings have been received. However there are many internal and external factors that can hinder, delay, or prevent acquisition and delivery of the notifications and patient information as intended by the clinician. These factors include: patient environment, data services, mobile device operating system and settings, clinic environment, schedule/configuration changes, or data processing.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs. Photo(s) on file at Abbott.

™ Indicates a trademark of the Abbott group of companies.

‡ Indicates a third party trademark, which is property of its respective owner.  
Bluetooth and Bluetooth logo are registered trademarks of Bluetooth SIG, Inc.

© 2020 Abbott. All Rights Reserved. 39196 MAT-2003918 v1.0 | Item approved for U.S. use only.

